Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R plus ) renal transplant recipients: Single-center experience

被引:7
|
作者
Khan, Salman [1 ]
Fischman, Clara [2 ]
Huprikar, Shirish [1 ]
机构
[1] Mt Sinai Hosp, Div Infect Dis, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
关键词
CMV prophylaxis; low-dose valganciclovir recipient positive; renal transplant recipients; PREVENTION; EFFICACY; DISEASE; SAFETY; DONOR;
D O I
10.1111/tid.12780
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Renal transplant recipients (RTR) who are seropositive for CMV (R+) are considered to be at intermediate risk for CMV disease. Current guidelines recommend high-dose valganciclovir (VGCV) prophylaxis because of limited data on the efficacy of low-dose VGCV. We describe our experience with using low-dose VGCV in R+ RTR. We retrospectively reviewed a cohort of 316 R+ RTR at our institution between 2002 and 2006. The primary endpoint was CMV disease at 1 year post transplant. The incidence of CMV disease at 12 months after transplantation was only 3% (6/221) in the D+R+ and 4% (4/95) in the D-R+ RTR. Low-dose VGCV was effective at preventing CMV disease in intermediate-risk (R+) RTR.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience
    Baghban, A.
    Belfield, K.
    Azar, M.
    Cohen, E.
    Malinis, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 503 - 503
  • [2] Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients
    Khan, Salman
    Sullivan, Timothy
    Ali, Mohsin
    Dunn, Dallas
    Patel, Gopi
    Huprikar, Shirish
    LIVER TRANSPLANTATION, 2018, 24 (05) : 616 - 622
  • [3] Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients
    Li, Yihan
    Pluckrose, Dawn M.
    Patolia, Roshani
    Arnouk, Serena
    Dubrovskaya, Yanina
    Papadopoulos, John
    Jonchhe, Srijana
    ANNALS OF PHARMACOTHERAPY, 2025, 59 (01) : 34 - 40
  • [4] Standard-versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients.
    Wilson, N.
    Sulejmani, N.
    Jantz, A.
    Patel, A.
    Summers, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 532 - 532
  • [5] Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Heart Transplant Recipients
    Julian, K. G.
    Shattahi, E.
    Burg, J. E.
    Boehmer, J. P.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (09) : 3414 - 3417
  • [6] Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study
    Korneffel, Katie
    Mitro, Graham
    Buschor, Kellie
    Rees, Michael
    Ortiz, Jorge
    TRANSPLANT IMMUNOLOGY, 2019, 56
  • [7] Valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant recipients: a single-center experience
    Iida, Takaya
    Miura, Kenichiro
    Ban, Hideki
    Ando, Taro
    Shirai, Yoko
    Ishiwa, Sho
    Shiratori, Atsutoshi
    Kaneko, Naoto
    Yabuuchi, Tomoo
    Ishizuka, Kiyonobu
    Takaiwa, Masanori
    Suyama, Kazuhide
    Hisano, Masataka
    Hattori, Motoshi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (05) : 531 - 536
  • [8] Valganciclovir prophylaxis for cytomegalovirus infection in pediatric kidney transplant recipients: a single-center experience
    Takaya Iida
    Kenichiro Miura
    Hideki Ban
    Taro Ando
    Yoko Shirai
    Sho Ishiwa
    Atsutoshi Shiratori
    Naoto Kaneko
    Tomoo Yabuuchi
    Kiyonobu Ishizuka
    Masanori Takaiwa
    Kazuhide Suyama
    Masataka Hisano
    Motoshi Hattori
    Clinical and Experimental Nephrology, 2021, 25 : 531 - 536
  • [9] Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis
    Gabardi, S
    Magee, CC
    Baroletti, SA
    Powelson, JA
    Cina, JL
    Chandraker, AK
    PHARMACOTHERAPY, 2004, 24 (10): : 1323 - 1330
  • [10] Low-Dose Valacyclovir Prophylaxis for Cytomegalovirus Infection in Renal Transplant Recipients with Intermediate Risk.
    Velioglu, A.
    Arikan, H.
    Asicioglu, E.
    Alagoz, S.
    Seyahi, N.
    Tuglular, S.
    Ozener, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 829 - 830